Published in Br J Cancer on July 05, 2004
Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci U S A (2005) 1.52
Multiple G-protein-coupling specificity of beta-adrenoceptor in macrophages. Immunology (2007) 0.86
Loss of Prkar1a leads to Bcl-2 family protein induction and cachexia in mice. Cell Death Differ (2014) 0.84
Quantitative proteomics analysis of the cAMP/protein kinase A signaling pathway. Biochemistry (2012) 0.80
Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol (1988) 6.51
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
Dominant negative MYC blocks transformation by ABL oncogenes. Cell (1992) 2.64
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A (2001) 2.58
Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther (2000) 1.64
cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol (1995) 1.33
Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages. Mol Cell Biol (1995) 1.29
Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. Mol Cell Biol (1997) 1.03
Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients Clin Cancer Res (1995) 1.02
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res (1998) 1.02
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clin Cancer Res (1999) 0.97
A method for obtaining high quality chromosome preparations from single hemopoietic colonies on a routine basis. Cancer Genet Cytogenet (1981) 0.95
The role of myc in transformation by BCR-ABL. Leuk Lymphoma (1993) 0.94
Transforming growth factor-beta 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells. J Biol Chem (2000) 0.89
Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas. Mol Cell Biol (1993) 0.83
p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene (1998) 0.83
Sensitive determination of 8-chloroadenosine 3',5'-monophosphate and 8-chloroadenosine in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1994) 0.81
Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (1994) 0.79
BCR/ABL and leukemia. Leuk Res (1996) 0.78
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem (1993) 7.16
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature (1993) 5.23
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature (1999) 3.99
cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem (2003) 3.24
CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 3.06
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
The reduction of surgical wound infections by prophylactic parenteral cephaloridine. A controlled clinical trial. Br J Surg (1973) 2.99
The emerging role of the emergency care practitioner. Emerg Med J (2004) 2.95
Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet (1985) 2.88
Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 2.88
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Service profiling and outcomes benchmarking using the CORE-OM: toward practice-based evidence in the psychological therapies. Clinical Outcomes in Routine Evaluation-Outcome Measures. J Consult Clin Psychol (2001) 2.72
Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem (1993) 2.62
Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem (2001) 2.44
Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J (1997) 2.38
Phenomics: the systematic study of phenotypes on a genome-wide scale. Neuroscience (2009) 2.38
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol (2001) 2.36
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol (2000) 2.27
ELECTROCARDIOGRAPHIC CHANGES AFTER ANOXAEMIA AND EXERCISE IN ANGINA OF EFFORT. Br Heart J (1941) 2.26
Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol (1990) 2.24
Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol (1994) 2.18
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
Polycystic kidney disease re-evaluated: a population-based study. Q J Med (1991) 2.05
TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05
Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A (1996) 2.03
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene (1994) 2.01
Osteoporosis in patients with inflammatory bowel disease. Gut (1987) 1.95
Uroradiology: imaging in prostate cancer. Clin Radiol (2001) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. J Biol Chem (1995) 1.87
Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem (2000) 1.87
In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum (1997) 1.87
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
The reduction of surgical wound infections by topical cephaloridine: a controlled clinical trial. Br J Surg (1974) 1.77
A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene (2007) 1.76
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74
Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun (1994) 1.74
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
The Depression Screening Instrument (DSI): a device for the detection of depressive disorders in general practice. J Affect Disord (1989) 1.66
Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis (1999) 1.63
Dopaminergic activity and idiopathic edema. Hosp Community Psychiatry (1991) 1.63
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Polycystic ovary syndrome and bulimia. Fertil Steril (1991) 1.62
Deterioration of cycloserine in the tropics. Bull World Health Organ (1968) 1.61
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
Clinical trial of common treatments for low back pain in family practice. Br Med J (Clin Res Ed) (1985) 1.58
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53
Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol (1996) 1.52
Virus-induced immunosuppression. 1. Age at infection relates to a selective or generalized defect. Virology (1993) 1.50
Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene (2007) 1.50
Molecular and physiological effects of alpha-tropomyosin ablation in the mouse. Circ Res (1998) 1.50
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem (1994) 1.49
Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer (2004) 1.47
Post-partum follow-up of women with gestational diabetes mellitus from Northland, New Zealand. Diabet Med (2007) 1.47
Eating behaviour and attitudes to weight and shape in British women from three ethnic groups. Br J Psychiatry (1990) 1.45
Quantitation of the response of lymphocytes in culture to specific and non-specific stimulation. Int Arch Allergy Appl Immunol (1967) 1.44
The Bowdlerisation of psychiatry. Br J Psychiatry (1990) 1.41
Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol (1993) 1.40
Reports of the death of factor analysis are greatly exaggerated. Br J Psychiatry (1992) 1.40
Sexual health of adults working in pornographic films. Int J STD AIDS (2009) 1.40
Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res (1999) 1.39
Ondansetron in intractable nausea and vomiting. Lancet (1992) 1.39
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38
Preliminary investigation to establish prevalence and risk factors for being overweight in pet rabbits in Great Britain. Vet Rec (2012) 1.38
Asthma prevalence in 1973, 1988 and 2003. Thorax (2006) 1.38
Cloning and expression in Escherichia coli of the gene encoding the heat-modifiable major outer membrane protein of Haemophilus influenzae type b. Infect Immun (1987) 1.37
Aetiology and treatment of fronto-ethmoidal mucocele. J Laryngol Otol (1981) 1.36
Tyrosine phosphorylation of protein kinase C-delta in response to its activation. J Biol Chem (1994) 1.36
Measurement and psychotherapy. Evidence-based practice and practice-based evidence. Br J Psychiatry (2000) 1.34
Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene (1990) 1.33
Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology (2003) 1.32
Synaptic and neurotransmitter activation of cardiac vagal neurons in the nucleus ambiguus. Ann N Y Acad Sci (2001) 1.32
Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. EMBO J (1995) 1.32
Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis. Ann Rheum Dis (1988) 1.30
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol (1998) 1.30
Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol (2000) 1.29
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Congenital anomalies after prenatal ecstasy exposure. Lancet (1999) 1.26
European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA); an online database for rare chromosome abnormalities. Eur J Med Genet (2005) 1.26
What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ (1999) 1.25